WO2008012237A1 - Construction de multiples antigènes et leur utilisation - Google Patents

Construction de multiples antigènes et leur utilisation Download PDF

Info

Publication number
WO2008012237A1
WO2008012237A1 PCT/EP2007/057358 EP2007057358W WO2008012237A1 WO 2008012237 A1 WO2008012237 A1 WO 2008012237A1 EP 2007057358 W EP2007057358 W EP 2007057358W WO 2008012237 A1 WO2008012237 A1 WO 2008012237A1
Authority
WO
WIPO (PCT)
Prior art keywords
cea
sequence
her2
vector
nucleotides
Prior art date
Application number
PCT/EP2007/057358
Other languages
English (en)
Inventor
Luigi Aurisicchio
Gennaro Ciliberto
Nicola La Monica
Original Assignee
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa filed Critical Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Publication of WO2008012237A1 publication Critical patent/WO2008012237A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

L'invention concerne les vecteurs de l'adénovirus discistronique et plasmidiques exprimant tous deux l'antigène spécifique des tumeurs CEA à antigène carcinoembryonnaire ou une partie de celui-ci et l'antigène 2/neu du facteur de croissance de l'épiderme humain (HER2/neu) ou une partie de celui-ci. La présente invention concerne également des procédés d'induction d'une réponse immunitaire contre les tumeurs spécifiques CEA et/ou HER2 en utilisant les compositions et les molécules décrites ici. Les gènes CEA et HER2 codent les antigènes généralement associés au développement des carcinomes humains. La présente invention concerne des compositions et des procédés de déclenchement ou de stimulation de l'immunité aux produits protéiques exprimés par les antigènes spécifiques des tumeurs CEA et/ou HER2/neu, une expression de CEA et/ou d'HER2 aberrante étant associée à un carcinome ou à son développement. Les vecteurs dicistroniques de la présente invention sont utilisés dans des vaccins et des compositions pharmaceutiques dans la prévention et/ou le traitement du cancer.
PCT/EP2007/057358 2006-07-24 2007-07-17 Construction de multiples antigènes et leur utilisation WO2008012237A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83298006P 2006-07-24 2006-07-24
US60/832,980 2006-07-24

Publications (1)

Publication Number Publication Date
WO2008012237A1 true WO2008012237A1 (fr) 2008-01-31

Family

ID=38658170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/057358 WO2008012237A1 (fr) 2006-07-24 2007-07-17 Construction de multiples antigènes et leur utilisation

Country Status (1)

Country Link
WO (1) WO2008012237A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267742A1 (en) * 2014-04-10 2017-09-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
WO2017210579A1 (fr) * 2016-06-03 2017-12-07 Etubics Corporation Compositions et procédés de vaccination et d'immunothérapie tumorales impliquant her2/neu
CN110831624A (zh) * 2017-06-02 2020-02-21 埃特彼塞斯公司 涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法
EP3463440A4 (fr) * 2016-05-27 2020-04-15 Etubics Corporation Compositions de vaccins à base de néo-épitopes et leurs méthodes d'utilisation
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052917A2 (fr) * 2002-12-10 2004-06-24 Epimmune Inc. Peptides diriges contre des antigenes associes aux tumeurs hla-a1, a2 -a3,-a24,-b7,and -b44 et compositions
WO2005019455A1 (fr) * 2003-08-22 2005-03-03 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Gene de synthese codant pour un antigene carcino-embryonnaire de singe rhesus, et ses utilisations
WO2006008154A1 (fr) * 2004-07-21 2006-01-26 Curevac Gmbh Melange d'arnm pour la vaccination contre des maladies tumorales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052917A2 (fr) * 2002-12-10 2004-06-24 Epimmune Inc. Peptides diriges contre des antigenes associes aux tumeurs hla-a1, a2 -a3,-a24,-b7,and -b44 et compositions
WO2005019455A1 (fr) * 2003-08-22 2005-03-03 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Gene de synthese codant pour un antigene carcino-embryonnaire de singe rhesus, et ses utilisations
WO2006008154A1 (fr) * 2004-07-21 2006-01-26 Curevac Gmbh Melange d'arnm pour la vaccination contre des maladies tumorales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERNHARD H ET AL: "Vaccination against the HER-2/neu oncogenic protein", ENDOCRINE-RELATED CANCER, JOURNAL OF ENDOCRINOLOGY LTD., BRISTOL, GB, vol. 9, no. 1, March 2002 (2002-03-01), pages 33 - 44, XP003016518, ISSN: 1351-0088 *
FACCIABENE ANDREA ET AL: "DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection", January 2006, HUMAN GENE THERAPY, VOL. 17, NR. 1, PAGE(S) 81-92, ISSN: 1043-0342, XP002458937 *
KASS ERIK ET AL: "Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus", 1 February 1999, CANCER RESEARCH, VOL. 59, NR. 3, PAGE(S) 676-683, ISSN: 0008-5472, XP002458938 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015243849B2 (en) * 2014-04-10 2020-12-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
US11414486B2 (en) 2014-04-10 2022-08-16 Seattle Children's Hospital Transgene genetic tags and methods of use
US20170267742A1 (en) * 2014-04-10 2017-09-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
US11155616B2 (en) 2014-04-10 2021-10-26 Seattle Children's Hospital Drug regulated transgene expression
AU2021201679B2 (en) * 2014-04-10 2023-05-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US11123369B2 (en) 2015-08-07 2021-09-21 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
EP3463440A4 (fr) * 2016-05-27 2020-04-15 Etubics Corporation Compositions de vaccins à base de néo-épitopes et leurs méthodes d'utilisation
EP3735984A1 (fr) * 2016-05-27 2020-11-11 Etubics Corporation Compositions de vaccins à base de néo-épitopes et leurs méthodes d'utilisation
CN110234752A (zh) * 2016-06-03 2019-09-13 埃特彼塞斯公司 用于涉及her2/neu的肿瘤疫苗接种和免疫疗法的组合物和方法
JP2019521099A (ja) * 2016-06-03 2019-07-25 エトゥビクス コーポレーション Ｈｅｒ２／ｎｅｕを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
WO2017210579A1 (fr) * 2016-06-03 2017-12-07 Etubics Corporation Compositions et procédés de vaccination et d'immunothérapie tumorales impliquant her2/neu
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN110831624A (zh) * 2017-06-02 2020-02-21 埃特彼塞斯公司 涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法
CN110831624B (zh) * 2017-06-02 2024-04-16 埃特彼塞斯公司 涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法

Similar Documents

Publication Publication Date Title
US8188244B2 (en) Carcinoembryonic antigen fusions and uses thereof
US7662586B2 (en) Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
EP2076531B1 (fr) Protéine de fusion de transcriptase inverse de la télomérase, nucléotides qui codent pour elle et ses utilisations
WO2009002418A2 (fr) Épitopes peptidiques de lymphocytes t dérivés de l'antigène carcinoembryonnaire, analogues immunogènes, et leurs utilisation
WO2008012237A1 (fr) Construction de multiples antigènes et leur utilisation
US20070104685A1 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
US20060286114A1 (en) Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
ZA200606358B (en) Carcinoembryonic antigen fusions and uses thereof
US20060228335A1 (en) Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof
ZA200508013B (en) Synthetic gene encoding human carcinoembryonic antigen and use thereof
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07787624

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07787624

Country of ref document: EP

Kind code of ref document: A1